Long dividend histories add to their appeal

Both of these U.S. firms have a long history of rewarding investors with annual dividend increases. Notably, each is a leader in its industry, which further cuts your risk.
PFIZER INC. $45 is a buy. The company (New York symbol PFE; Income-Growth Dividend Payer Portfolio, Manufacturing sector; Shares… Read More

Key move for Merck

MERCK & CO. INC., $93.26, is a #1 Power Buy for 2022. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (www.merck.com; Shares outstanding: 2.5 billion; Market cap: $239.7 billion; Dividend yield: 3.0%) has now exercised an option to jointly develop and potentially sell an mRNA-based cancer vaccine along… Read More

Lilly targets RNA medicines

ELI LILLY & CO., $276.44, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 952.3 million; Market cap: $262.3 billion; Dividend yield: 1.4%) has announced that it’s building a new RNA medicine centre in Boston for $700 million. Eli Lilly’s investment in… Read More